Abnormal activity of injured ocular nerves evokes pain sensations in patients that have undergone refractive or cataract surgery. 

Current approved treatments are based on NSAIDs or corticosteroids, which have limited efficacy and considerable side effects (i.e. intraocular pressure) and thus are not suitable for long-term use due to safety concerns.

Post operative ocular pain pharmacological market size is above $0.5 billion with almost 5M of refractive and cataract surgeries conducted every year only in the US. 

Ocular pain is $10 billion global market including other diseases of the ocular surface that are commonly accompanied with pain.